Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Kathryn A. Gold, MD
Advertisement
Articles by Kathryn A. Gold, MD
Advertisement
Latest Updated Articles
Immunotherapeutic Approaches to the Management of Head and Neck CancerPublished: December 17th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
2
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
3
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
4
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
5
